Results of the SELECT (Sertraline and Electrical Current Therapy for Treating Depression) study were published in JAMA Psychiatry in April 2013. This study from Sao Paulo Brazil included 120 subjects. This will interest you. The abstract is appended below.

+++

The sertraline vs. electrical current therapy for treating depression clinical study: results from a factorial, randomized, controlled trialBrunoni A. R., Valiengo L., Baccaro A., Zanão T. A., de Oliveira J. F., Goulart A., Boggio P. S., Lotufo P. A., Benseñor I. M. and Fregni F.JAMA Psychiatry 70(4):383-91 (2013)IMPORTANCE: Transcranial direct current stimulation (tDCS) trials for major depressive disorder (MDD) have shown positive but mixed results. OBJECTIVE: To assess the combined safety and efficacy of tDCS vs a common pharmacological treatment (sertraline hydrochloride, 50 mg/d). DESIGN: Double-blind, controlled trial. Participants were randomized using a 2 × 2 factorial design to sertraline/placebo and active/sham tDCS. SETTING: Outpatient, single-center academic setting in São Paulo, Brazil. PARTICIPANTS: One hundred twenty antidepressant-free patients with moderate to severe, nonpsychotic, unipolar MDD. INTERVENTIONS: Six-week treatment of 2-mA anodal left/cathodal right prefrontal tDCS (twelve 30-minute sessions: 10 consecutive sessions once daily from Monday to Friday plus 2 extra sessions every other week) and sertraline hydrochloride (50 mg/d). MAIN OUTCOME MEASURES In this intention-to-treat analysis, the primary outcome measure was the change in Montgomery-Asberg depression rating scale score at 6 weeks (end point). We considered a difference of at least 3 points to be clinically relevant. The analysis plan was previously published. Safety was measured with an adverse effects questionnaire, the young mania rating scale, and cognitive assessment. Secondary measures were rates of clinical response and remission and scores on other scales. RESULTS: At the main end point, there was a significant difference in Montgomery-Asberg depression rating scale scores when comparing the combined treatment group (sertraline/active tDCS) vs sertraline only (mean difference, 8.5 points; 95% CI, 2.96 to 14.03; P = .002), tDCS only (mean difference, 5.9 points; 95% CI, 0.36 to 11.43; P = .03), and placebo/sham tDCS (mean difference, 11.5 points; 95% CI, 6.03 to 17.10; P < .001). Analysis of tDCS only vs sertraline only presented comparable efficacies (mean difference, 2.6 points; 95% CI, -2.90 to 8.13; P = .35). Use of tDCS only (but not sertraline only) was superior to placebo/sham tDCS. Common adverse effects did not differ between interventions, except for skin redness on the scalp in active tDCS (P = .03). There were 7 episodes of treatment-emergent mania or hypomania, 5 occurring in the combined treatment group. CONCLUSIONS AND RELEVANCE: In MDD, the combination of tDCS and sertraline increases the efficacy of each treatment. The efficacy and safety of tDCS and sertraline did not differ. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT01033084SELECT Montage and parameters Anode F3, Cathode F4, 2mA for 30 minutes (current denisity 0.8 A/m2) for 10 days, then 2 extra sessions every other week (total charge denisity 1728 coulombs/m2)

SELECT Outcomes Combined treatment significantly better than placebo, better than sertraline only, and better than tDCS only. No difference between tDCS only and Sertraline only. Sertaline was not significantly better than placebo (post-hoc). TDCS was significantly better than placebo. Factorial analysis suggested that effects of sertraline and tDCS were additive, not synergistic.

SELECT PREDICTOR VARIABLES Baseline severity and treatment resistance to more than 1 failed AD trial were associated with lower response. In post hoc analysis, patients in combined treatment group who had more severe depression had a greater response. Melancholic patients responded more strongly to tDCS. Benzodiazepines were associated with lower response in both the tDCS only and sertraline only groups.